Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Slides:

Advertisements

Similar presentations

Pulmonary Stereotactic Ablative Radiotherapy:

Advertisements

The Health Roundtable 1-1b_HRT1215-Session_HEGI_JOHNSON_WESTMEAD_NSW Volumetric Modulated Arc Therapy for Stereotactic Body Radiotherapy in Early Lung.

Cancer.orgPredict Results of a multicentric in silico clinical trial (ROCOCO): comparing radiotherapy with photons and protons for non-small cell lung.

Tumor Location Correlates with Radiation Pneumonitis after Stereotactic Body Radiation Therapy (SBRT) for Primary and Oligometastatic Lesions of the Lung.

Figure 1 Estimated annual percentages of new

Figure 1. (a) Dose distribution of dynamic conformal photon therapy

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Response after initial increase in total tumour burden

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Response after appearance of a new lesion

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Concept of the therapeutic index

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 2 Multiscale modelling in oncology

Insert tables Insert graphs Insert figure

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 3 Intracranial targeting of high-grade gliomas

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Figure 5 Identification of mucinous carcinoma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 6 Double opposed-field irradiation of an idealized geometry

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 Proposed treatment algorithm for advanced gastroesophageal cancer based on publish recommendations Figure 1 | Proposed treatment algorithm for.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Example of a patients with CUP

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Imaging of atherosclerotic plaque burden

Nat. Rev. Urol. doi: /nrurol

Figure 5 The biological effects of charged particles

Figure 3 Drug cycling with collateral sensitivity

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

chemotherapy for patients with MC versus those with AC

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Dosimetric comparison of LDR‑BT versus HDR‑BT

Figure 1 NIR fluorescence is more suitable for

Figure 2 Nonmalignant tissue can be spared from radiation

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Host immune responses, not the radiosensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Joshua E. Rosen, BASc, Michelle C

Prophylactic Cranial Irradiation (PCI) versus Active MRI Surveillance for Small Cell Lung Cancer: The Case for Equipoise Chad G. Rusthoven, MD, Brian.

Figure 2 Frequency and overlap of alterations

Figure 2 Variations between planned and delivered doses of radiation

Figure 2 The evolution of brachytherapy for prostate cancer

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Radiogenomics analysis can reveal relationships

Figure 1 Overview of the imaging biomarker roadmap

Figure 3 Target volume definitions

Figure 3 Determination of the primary site

The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up. The best response for.

A, Changes in BRAFV600E cfDNA allele fraction from baseline after one dose of treatment for 12 patients with serial samples available, classified according.

Presentation transcript:

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT) or charged-particle therapy (CPT) for two patients with NSCLC Figure 4 | Treatment plans using stereotactic body radiotherapy (SBRT) or charged-particle therapy (CPT) for two patients with NSCLC. Patient one is more likely to benefit from CPT than from SBRT owing to the large integral dose necessary to treat multiple lesions with X-rays. Conversely, patient two is more likely to benefit from SBRT than from CPT owing to the small size of the lesion (1.6 cm3) and its location in a central region of the lung, which would result in a larger planning target volume (PTV) with CPT than with SBRT (32 cm3 versus 7.7 cm3). The clinical target volume contour is outlined in white. Image part of an in silico trial for comparison of SBRT and CPT with carbon ions72, modified from Anderle, K. et al. In silico comparison of photons versus carbon ions in single fraction therapy of lung cancer. Phys. Medica 32, 1118–1123 (2016), with permission from Elsevier. Image part of an in silico trial for comparison of SBRT and CPT with carbon ions72, modified from Anderle, K. et al. In silico comparison of photons versus carbon ions in single fraction therapy of lung cancer. Phys. Medica 32, 1118–1123 (2016c), with permission from Elsevier. Durante, M. et al. (2017) Charged-particle therapy in cancer: clinical uses and future perspectives Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2017.30